Research Pasatru approved by FDA as 2nd drug for rare bone lesion diseaseBy Healthcare Propulsion StaffAugust 20, 20260 After more than 10 years in development, Regeneron secured a landmark approval for its monoclonal antibody garetosmab, now commercially known…
